First-in-Class Disease-Targeting Treatment in Europe

On February 9, 2024, the European Commission approved Biogen's (BIIB) Skyclarys (omaveloxolone) for the treatment of Friedrich's ataxia in patients aged 16 years and older. The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on December 14, 2023. The FDA in the United States approved the same age group on February 28, 2023, without a committee vote. This once-daily oral treatment is the first approved drug for Friedrich's ataxia in Europe, moving beyond existing supportive care that relies on physical and occupational therapy, as well as management of cardiomyopathy and diabetes, to directly target the progression of the disease. The regulatory status in both the United States and Europe is now Marketed.

Nrf2 Activation and MOXIe Clinical Evidence

Omaveloxolone is a small-molecule therapeutic that activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, thereby enhancing mitochondrial function, antioxidant responses, and cellular energy production. The approval is based on the MOXIe Part 2 Phase 2 randomized, double-blind, placebo-controlled trial (NCT02255435), which included 103 patients aged 16 to 40 years. In the primary analysis population of 82 patients without pes cavus, the modified Friedreich's Ataxia Rating Scale (mFARS) score at week 48 decreased by approximately 1.6 points in the treatment group and increased by approximately 0.9 points in the placebo group, resulting in a least squares mean difference of -2.40 and a p-value of 0.014. The reduction in the rate of functional decline in this progressive rare neuromuscular disease is a key factor in the regulatory decision, but monitoring of liver enzymes, lipid levels, and B-type natriuretic peptide before and after treatment is required.

Commercial Performance Supporting Acquisition Price

Biogen completed the acquisition of Reata Pharmaceuticals on September 26, 2023, securing Skyclarys and its follow-up pipeline. The announced enterprise value was $172.50 per share, or approximately $7.3 billion, and the accounting value of the transaction was $7.1934 billion, including cash payments and stock compensation for pre-acquisition service. Skyclarys' global revenue in 2025 is projected to be $520.5 million, a 36.1% increase from $382.5 million in 2024, with revenue outside the United States reaching $209.9 million due to the expansion of launches in Europe and the Middle East. The actual revenue growth demonstrates the market value of rare diseases, but in Europe, the pace of price and reimbursement negotiations in each country will determine the patient penetration rate and return on investment.

Subsequent Competitors Pressuring the Monopolistic Market

Currently, Skyclarys is the only approved drug for the same indication, giving Biogen a first-mover advantage in the European standard of care. PTC Therapeutics' (PTCT) 15-lipoxygenase inhibitor, vatiquinone, received a complete response letter from the FDA on August 19, 2025, citing a lack of substantial evidence of effectiveness, and the company plans to initiate a 24-month open-label registration trial in the third quarter of 2026. Larimar Therapeutics' (LRMR) pratanex protein replacement therapy, nomlabofusp, submitted the first module of a sequential BLA for accelerated approval based on Phase 2 and open-label extension data, with the first patient enrolled in the confirmatory Phase 3 trial in the third quarter of 2026. Therefore, while the short-term monopoly is solid, the regulatory progress of nomlabofusp, which addresses the pratanex deficiency itself, is a key variable that will change the mid-term pricing power and combination/alternative treatment landscape.